ATRC (AtriCure) YoY EPS Growth: 238.46% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATRC AtriCure Inc ATRC
79 GF Score
Price $51.66
GF Value $39.70
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is AtriCure YoY EPS Growth?

AtriCure ATRC -1.52% 79 YoY EPS Growth is 238.46% as of Jun. 2026. GuruFocus rates ATRC with a GF Score™ of 79/100 and a GF Value™ of $39.70 (Modestly Overvalued). The stock has 6 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. AtriCure's YoY EPS Growth for the quarter that ended in Jun. 2026 was 238.46%.

AtriCure's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $0.18.

AtriCure YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for AtriCure's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtriCure YoY EPS Growth Chart

AtriCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 195.61 -193.58 35.29 -43.94 74.74

AtriCure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.53 94.12 112.12 100.00 238.46
ATRC
79GF Score
AtriCure Inc ATRC
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AtriCure YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

AtriCure's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-0.24--0.95)/ | -0.95 |
=74.74 %

AtriCure's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(0.18--0.13)/ | -0.13 |
=238.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 238.46% mean?
AtriCure (ATRC) has a YoY EPS Growth of 238.46% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for AtriCure and its competitors.
Is AtriCure's YoY EPS Growth too high?
AtriCure's current YoY EPS Growth is 238.46%. Overall, AtriCure has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's YoY EPS Growth compare to XRAY and WRBY?
AtriCure's YoY EPS Growth of 238.46% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for AtriCure and its competitors. AtriCure's current YoY EPS Growth is 238.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Overvalued. The stock's GF Value™ is $39.70, compared to a current price of $51.66 — trading 30.1% above its estimated fair value. The current YoY EPS Growth is 238.46%. AtriCure's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For AtriCure (ATRC), the current YoY EPS Growth is 238.46% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtriCure (ATRC) Overvalued in 2026?

Based on GuruFocus' analysis, AtriCure stock appears to be overvalued. The current stock price of $51.66 is trading 30.1% above its estimated GF Value™ of $39.70. GuruFocus considers AtriCure to be Modestly Overvalued.

Key valuation signals for ATRC:

  • YoY EPS Growth: 238.46%
  • GF Value™: $39.70 vs. price of $51.66 (30.1% above fair value)
  • GF Score™: 79/100 with 6 warning signs

No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtriCure Business Description

Other Exchanges A5I:Germany
Address 7555 Innovation Way, Mason, OH, USA, 45040
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
79GF Score

Get the complete analysis for ATRC

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.66
Price
$39.70
GF Value